Lesinurad / allopurinol Medicine 09 January 2018 Extended indication Hyperuricaemia in patients with gout Therapeutic value No judgement Total cost Registration phase Registration application pending Product Active substance Lesinurad / allopurinol Domain Chronic immune diseases Reason of inclusion Main indication Other chronic immune diseases Extended indication Hyperuricaemia in patients with gout Current proprietary name Already available biosimilars / generics Proprietary name Duzallo Manufacturer Grunenthal Portfolio holder Mechanism of action Unknown Route of administration Oral Therapeutical formulation Tablet Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity New medicine ATMP Unknown Submission date August 2017 Expected Registration September 2018 Orphan drug No Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 1 times a day Dosage per administration 200/200 mg References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost € 3,000.00 - 5,000.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References GoodRx.com Additional remarks Dit betreft een combinatietherapie, prijs zal wel iets omhoog gaan maar naar verwachting niet veel ten opzichte van monotherapie. Prijs in de VS ongeveer $400 voor 30 tabletten 200/200 mg. Dat komt dus neer op ongeveer $4.800 op jaarbasis. Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks